News

Newron announces nominations to its Board of Directors at upcoming Annual General Meeting

George Garibaldi and Paolo Zocchi proposed as new independent, non-executive Board members Patrick Langlois and Luca Benatti to step down after long-standing service Full Annual

Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program

Ad hoc announcement pursuant to Art. 53 LR Proceeds expected to fund global ENIGMA-TRS studies and extend cash runway beyond pivotal 12-week results, supporting development of

Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia

Publication presents clinical findings highlighting evenamide’s glutamatergic modulation as a therapeutic strategy for patients with inadequate response or treatment-resistant

EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan

Milan, Italy, and Morristown, NJ, USA, January 7, 2026 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development

Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent

Ad hoc announcement pursuant to Art. 53 LR EP4615820 – “Crystalline Forms of Evenamide” is expected to extend asset exclusivity in EU into 2044 Evenamide is currently being